Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Regeneron Pharmaceuticals Inc (REGN.O)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date Stock Price (US$) Price Target (US$) Rating
2022-02-28618.36770.00Buy
2022-10-21713.91823.00Buy
2022-11-07750.93862.00Buy
2023-01-29742.83863.00Buy
2023-02-08749.66914.00Buy
2023-04-20798.10926.00Buy
2023-07-24727.13912.00Buy
2023-08-04766.44895.00Buy
2023-11-01791.27907.00Buy
2023-11-03816.90966.00Buy
2024-01-24948.241112.00Buy
2024-02-05936.331090.00Buy
2024-04-17901.191099.00Buy
2024-05-06958.641124.00Buy
2024-07-121100.051250.00Buy
2024-08-011093.141251.00Buy
2024-10-31838.201130.00Buy
2025-01-15703.43738.00Neutral
2025-02-04697.05768.00Neutral
2025-04-29568.91633.00Neutral

Disclosures

  • UBS Securities LLC makes a market in the securities and/or ADRs of this company.
  • UBS holds a long or short position of 0.5% or more of the listed shares of this company.
Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.